Active Components of Kratom
Kratom contains over 40 alkaloids, with mitragynine and 7-hydroxymitragynine being the two primary psychoactive compounds responsible for its opioid-like and stimulant effects 1, 2.
Primary Active Alkaloids
The main molecular constituents are:
Mitragynine: The most abundant alkaloid, typically found at concentrations of 13.9-270 mg/g in commercial products 3. This is the predominant compound responsible for kratom's effects.
7-hydroxymitragynine (7-OH-MG): The second major psychoactive alkaloid, though present in much lower concentrations than mitragynine 4, 2.
Both compounds act as partial agonists at μ-opioid receptors and antagonists at κ- and δ-opioid receptors, with additional effects at adrenergic, serotonergic, and dopaminergic pathways 4, 2. Notably, they lack effects on β-arrestin, which may explain kratom's potentially better tolerability profile compared to classical opioids 4.
Secondary Alkaloids
Beyond the two primary compounds, kratom contains numerous other indole and oxindole alkaloids that contribute to its overall pharmacological profile 3:
Major secondary indole alkaloids (quantifiable in commercial products):
- Paynantheine
- Speciociliatine
- Speciogynine
- Mitraciliatine
- Isopaynantheine
- Ajmalicine
- Corynantheidine
Oxindole alkaloids (present in varying concentrations):
- Isomitraphylline
- Isospeciofoleine
- Speciofoline
- Corynoxine A and B
- Corynoxeine
- Rhynchophylline
- Mitraphylline
Pharmacokinetic Considerations
Only four alkaloids show significant systemic exposure 8 hours after oral consumption: mitragynine, 7-hydroxymitragynine, speciociliatine, and corynantheidine 5. Paynantheine and speciogynine are detectable only up to 1 hour post-dose, while other alkaloids show minimal to no systemic absorption 5.
Critical Clinical Caveat
The alkaloid profile varies significantly between products and preparation methods 3, 6. Commercial products typically show high mitragynine content (13.9-270 mg/g), while certain plant chemotypes (like US-grown "Rifat" strain) may have elevated speciogynine instead 3. Despite marketing claims about different "strains" having distinct effects, laboratory analyses reveal no significant cross-strain differences in alkaloid content, suggesting effect differences may be influenced more by placebo and marketing narratives than actual chemical composition 6.
Important drug interaction warning: Several kratom alkaloids inhibit CYP2D6 and, to a lesser extent, CYP2C19 and CYP3A4 enzymes 1, 4, creating significant potential for drug-drug interactions in the perioperative and clinical setting.